Sales & Marketing M&A trends in diagnostics and life sciences tools The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large corporates.
News Tarsus places $800m wager on Alkeus' Stargardt therapy Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."
News Sources quash rumours of an AZ/BMS mega-merger A media report suggests there is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb.
News Curium strikes $8bn deal to buy radiopharma rival Lantheus Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
News CNS-focused Supernus and Indivior agree merger terms Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new CNS-focused company with annual sales of $2.2bn.
News Are we about to see a return for the pharma mega-merger? There are rumours that the first pharma 'mega-merger' for several years – between AstraZeneca and Bristol Myers Squibb – is under discussion.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.